Cabozantinib (Cabometyx, Cometriq)
Targeted Therapy · Approved since 2012
Description
Cabozantinib is an oral multi-kinase inhibitor that targets several receptor tyrosine kinases involved in tumor growth and angiogenesis. While approved for renal cell carcinoma and hepatocellular carcinoma, cabozantinib is used off-label in colorectal cancer treatment, particularly in patients with specific molecular alterations. The drug shows activity against tumors harboring MET amplifications or RET fusions, which can occur in a subset of colorectal cancers.
Mechanism of Action
Cabozantinib simultaneously inhibits multiple tyrosine kinases including VEGFR2, MET, AXL, RET, and KIT. By blocking these pathways, it disrupts both tumor angiogenesis and direct tumor cell growth signaling, particularly in cancers dependent on MET or RET signaling for proliferation and survival.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Cabometyx, Cometriq |
| Category | Targeted Therapy |
 Status | Off-label |
 EMA Status | EMA Approved |
 Spain Access | Hospital use off-label in CRC |
| Administration | Oral |
| Year Approved | 2012 |
| Clinical Trials | 12 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.